ReviewCurrent medical science2025
Key Transcription Factors: Avenue for Treating Alcoholic Liver Disease.
Review in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Iron-Sulfur Cluster Targeting: A Novel Perspective for Treating Alcohol-Related Lipid Metabolic Diseases.Journal of biochemical and molecular toxicology · 2026Review
- B-Cell Receptor-Associated Protein 31 Deficiency Aggravates Ethanol-Induced Liver Steatosis and Liver Injury via Attenuating Fatty Acid Oxidation and Glycogen Synthesis.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alcoholic liver disease (ALD), which includes a range of diseases, ranging from alcoholic steatosis, hepatitis, and fibrosis to cirrhosis and hepatocarcinoma, is a process of epigenetic remodeling involving multiple genes and metabolic pathways. ALD is involved in various transcriptional regulatory mechanisms, including lipid metabolism disorders, inflammatory responses, autophagy, fibrogenesis, oxidative stress, fatty acid metabolism, iron metabolism, and endoplasmic reticulum stress. In the occurrence of ALD and its response to the microenvironment, various transcription factors (TFs) play important roles. Targeted therapy involving these TFs may pave a novel avenue for the treatment of ALD. Here, we summarize the molecular characteristics of TFs and their involvement in the biological and pathological processes of ALD. We further discuss the current pharmaceutical treatments targeting these TFs and their mediators. This study provides detailed and accurate regulation maps of TFs for the targeted therapy of ALD.
Indexed as
Identifiers
40622435What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.